VIVOS THERAP. DL-,0001

Vivos Therapeutics (NASDAQ:VVOS) said its cost-cutting initiatives drove a significant reduction in its net loss during the second quarter when compared to the same period in 2022.  For the three months ended June 30, 2023, the company reduced its net loss by 21% to $1.5 million when compared to the year-ago quarter. » Mehr auf proactiveinvestors.com

LITTLETON, Colo., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, today announced that the Company intends to release its second quarter 2023 financial results after market close today, Wednesday, August 16, 2023. » Mehr auf globenewswire.com

LITTLETON, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, today announced it will reschedule its conference call to review its financial results for the second quarter ended June 30, 2023, previously scheduled for today at 5:00 p.m. (Eastern Time). Further details for the second quarter financial results conference call will be provided in a subsequent announcement. » Mehr auf globenewswire.com